Abstract Purpose Magnetic particle imaging (MPI) and fluorine-19 ( 19 F) MRI produce images which allow for quantification of labeled cells. MPI is an emerging instrument for cell tracking, which is expected to have superior sensitivity compared to 19 F MRI. Our objective is to assess the cellular sensitivity of MPI and 19 F MRI for detection of mesenchymal stem cells (MSC) and breast cancer cells. Methods Cells were labeled with ferucarbotran or perfluoropolyether, for imaging on a preclinical MPI system or 3 Tesla clinical MRI, respectively. In vivo sensitivity with MPI and 19 F MRI was evaluated by imaging MSC that were administered by different routes. Results Using the same imaging time, as few as 4000 MSC (76 ng iron) and 8000 breast cancer cells (74 ng iron) were reliably detected with MPI, and 256,000 MSC (9.01 × 10 16 19 F atoms) were detected with 19 F MRI, with SNR &gt; 5. In vivo imaging revealed reduced sensitivity compared to ex vivo cell pellets of the same cell number. Conclusion MPI has the potential to be more sensitive than 19 F MRI for cell tracking. We attribute reduced MPI and 19 F MRI cell detection in vivo to the effect of cell dispersion among other factors, which are described.

The sensitivity of magnetic particle imaging and fluorine-19 magnetic resonance imaging for cell tracking